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Dry eye (DE) is a multifactorial disease of the tears and
ocular surface that results in symptoms of discomfort, visual
disturbance, and tear film instability with potential damage
to the ocular surface, accompanied by increased osmolarity
of the tear film and inflammation of the ocular surface.1 Esti-
mated prevalence ranges from about 5% to over 35% in dif-
ferent age groups.2 Despite its high prevalence, DE is
frequently under-recognized. Owing to its negative influence
on patients’ visual function and quality of life, DE represents a
big burden in public healthcare. Therefore, attempts to find
better diagnostic approaches and appropriate treatment
for DE are worthy of consideration. This review discusses
the classification, diagnostic approaches and treatments of
DE.Classification
The major classes of DE, as identified by the International
Dry Eye Workshop (DEWS) report are aqueous deficient dryeye (ADDE) and evaporative dry eye (EDE).1 Although both
ADDE and EDE present with similar signs of reduced stability
and increased tear film osmolarity, ADDE chiefly refers to a
failure of lacrimal secretion and EDE is due to excessive water
loss from the exposed ocular surface in the presence of
normal lacrimal secretory function. It is also important to
recognize that ADDE and EDE may coexist. The main
etiopathogenic classification is illustrated in Fig. 1.Diagnostic assessment
Although literature provides an extensive discussion on
the role and appropriateness of currently used tests to diag-
nose DE, there is no gold standard test or even a panel of
tests or well-established cutoff values for the available tests.3
The suggested sequence of DE diagnostic tests is: history
and examination followed by a symptom questionnaire; tear
break-up time and ocular surface fluorescein staining; Schir-
mer test; lid and meibomian morphology and meibomian
expression.2 In Delphi panel, the most frequently cited tests
were slit-lamp examination and fluorescein staining (100%)e:
al.com
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Figure 1. Etiopathogenic classification (modified from 2007 DWES report).1
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94%).3 An ideal diagnostic method should be preferably
noninvasive, objective, specific, reproducible and sustainable
in terms of cost and time. At present, none of the current
tests for DE diagnosis altogether meet these features.
Subjective evaluation
The symptoms and history of DE patients vary widely;
therefore, validated questionnaires have been developed to
ensure consistency in recording symptomatic information. A
comparative listing of DE questionnaires is available in the
report of the Epidemiology Subcommittee of the Interna-
tional DEWS 2007.2 Previously it was believed that DE can
be diagnosed largely on the basis of symptoms; however,
recent studies have questioned this opinion as there is often
a lack of correlation between the severity of the symptoms
and signs of DE.4 This lack of consistency between signs
and symptoms presents a problem not only in the diagnosis
of the disease, but also in assessment of severity and in the
evaluation of the clinical efficacy of treatments.
Objective evaluation
A scientific roundtable on dry eye ranked tear break up
time (93%), corneal staining (85%), tear film assessment
(76%), conjunctival staining (74%), and the Schirmer test
(54%) as the most commonly used diagnostic tests for initial
assessment of dry eye.5 Apart from these traditional clinical
tests, we will discuss more about the less invasive evaluations
based on the recently developed technologies related to tear
hyperosmolarity, tear film instability and inflammation.Tear osmolarity
An increase in tear osmolarity is common to all types of
DE. It is suggested that osmolarity values greater than 308
mOsms/l are a sensitive indicator of mild DE and values
greater than 312 mOsms/l are indicative of moderate to
severe DE (sensitivity 73%; specificity 92%).6 The difference
in the tear osmolarity values among normal, mild, moderateor severe dry eye patients is so small that precision is critical.
Tear film osmolarity can be measured in three ways: freezing
point depression (FPD), (considered to be the gold stan-
dard);7 vapor pressure8 and electrical conductivity or imped-
ance.9 Since the electrical impedance of tear samples
requires a small sample size (0.05 ll) and short test duration
(30 s), it is considered more suitable for clinical use.10 The
TearLab system (TearLab Inc., San Diego, CA, USA) uses this
method to determine tear osmolarity. While recent studies
have demonstrated the correlation between increased osmo-
larity and DE disease severity, it is also observed that ‘‘tear
osmolarity cannot be used as the sole indicator of dry eye
disease’’.11
Assessment of tear stability
The measurement of tear film stability is fundamental to
the diagnosis of dry eye.12 A variety of methods are available
to assess different aspects of the tear film and provide
insights into its ‘‘stability’’. Tear break-up time (TBUT), intro-
duced by Norn,13 remains the most frequently used diagnos-
tic test to determine tear film instability.14 Generally, the non-
invasive tear break-up time (NIBUT) involves the observation
of an illuminated grid pattern reflected from the anterior tear
surface. NIBUT can be measured by corneal topography,
interferometry, aberrometry, functional visual acuity assess-
ment, and confocal microscopy. A regular image of the
reflected target indicates a stable tear film. The time (in
seconds) from the last blink to the appearance of the first
discontinuity or break in the reflected image is recorded.Tear film particle assessment
Non-invasive tear film particle assessment technique to
measure tear film’s upward spread and stability can poten-
tially be used for the precise and objective evaluation of tear
film.12,15 Tear film particle velocity is measured as an assess-
ment of tear hydrodynamics by tracking the movement of
reflective particles in the tear film. Digital images of the cen-
tral region of the ocular surface are collected for 10 s to visu-
alize the naturally seen particles in the tear film following a
Dry eye disease 175natural blink. Software determines the velocity of the
particles as they traverse upwards in the tear film. This tech-
nique has been applied to the pre-contact lens tear film to
differentiate the wetting characteristics of various contact
lens materials, but can potentially be used for clinical evalua-
tion of tear film stability more precisely and objectively.Topographical analysis systems
Corneal topography systems like TMS-116 and high speed
videokeratoscopy (HSV)17 have replaced keratometers in clin-
ical settings to evaluate indices like surface regularity index
(SRI), surface asymmetry index (SAI) and topographic pattern
– that can be used to evaluate corneal surface regularity and
tear film stability. These videokeratoscopy indices enable
objective quantification of the quality of the tear film, its
breakdown and also consequent effects on image quality.18
According to a 2008 survey, most of the experts chose video-
keratoscopy for initial evaluation of post-LASIK dry eye.14Interferometry
Interferometry is based on the colored fringes that arise
from interference between light reflected from the surface
of the lipid layer and from the interface between the lipid
layer and the aqueous layer of the tear film. These interfer-
ence patterns could be used to observe the nature, thickness
and rupture of the lipid layer.19 Besides lipid layer thickness,
interferometry can also measure NIBUT i.e., the time
between the last blink and the appearance of the first lipid
layer discontinuity. LipiView (TearScience Inc., Morrisville,
NC) is a commercially available interferometer that provides
quantitative values of the tear-film lipid layer thickness
(LLT), and this automated assessment of the LLT might be a
suitable screening test for detecting meibomian gland
dysfunction (MGD).20 Other instruments, software and
prototypes are also being developed.21,22Aberrometry
Wavefront aberrometry allows the non-invasive assess-
ment of the visual disturbances caused by higher order aber-
rations arising from tear film instability and break-up. Any
local changes in tear film thickness and regularity such as
those associated with tear break-up introduce aberrations
and subsequently reduce retinal image quality. Changes in
tear volume and dynamics induce changes in higher order
aberrations, which appear as characteristic patterns in both
normal and dry eyes.18,23,24 Low tear volumes in severe DE
may cause increased, but stable, aberrations. This may be
the result of irregular, damaged epithelium in the optic zone
in the absence of dynamic tear film changes.25 The instillation
of artificial tears has been shown to reduce aberrations in dry
eye when the measurement is taken after several seconds26;
however, when measured 2 s after a blink, an initial increase
in aberrations was found because of the tear film distur-
bances induced by increase in tear volume.27 A paper pre-
sented at a recent conference suggested that aberrometry
could be utilized for not only detecting DE but also for
monitoring the efficacy of treatments.28Functional visual acuity
Despite normal conventional visual acuity, DE patients
often complain about decreased visual acuity when driving,
reading, and using a computer. Since the ocular surface
tends to dry out when normal blinking is suppressed during
gazing, patients with dry eye may have problems maintaining
clear vision while gazing. To simulate visual acuity while
gazing, functional visual acuity (FVA) was conceptualized.
FVA is a measure of visual acuity during sustained eye
opening without blinking.
FVA was originally defined as the monocular recognition
acuity at a specific time point. Later studies used a range of
values, as well as the visual maintenance ratio (the ratio
between the FVA and the baseline visual acuity) to reflect
everyday vision more accurately.29 It has been documented
that FVA decreases significantly in both non-Sjögren’s syn-
drome (NSS) and Sjögren’s syndrome (SS) dry eye patients.30
Despite the criticism that patients are required to keep their
eyes open longer than normal, FVA tests have been com-
monly used to assess visual disturbances in DE patients. To
further improve FVA measurements, a new continuous FVA
measurement system (FVAM, NIDEK, Gamagori, Japan) was
developed, which allows continuous monocular visual acuity
measurement during a 30 s blink-free period.31 The method-
ology has been useful for evaluating patients with tear
instability and it has been reported that the assessments
correlate with TBUT.32Optical coherence tomography
The anterior segment optical coherence tomography
(OCT) can measure the tear film thickness33 and tear menis-
cus parameters34 which indicate total tear volume. Due to
its high resolution, non-invasiveness, good accuracy, and
repeatability, OCT is a useful tool to diagnose DE. Nguyen
et al. found that lower tear meniscus measurement with Fou-
rier-domain-OCT correlates well with symptoms of DE and
the Schirmer test.35 Shen suggested that lower tear meniscus
height and radius were the best indicators of DE with a cut-
off meniscus height of 1.64 mm and radius of 1.82 mm.34 It
is important to factor in the role of tear secretion, location
of the punctum, lacrimal drainage, lid length, eyelid tension,
and palpebral aperture while interpreting tear meniscus
dimensions. Additionally, OCT has recently been used to
grade lid parallel conjunctival folds (LIPCOF),36 to map 3-
dimensional corneal epithelial thickness,37 and to investigate
meibomian gland structures based on the more developed
techniques,38 which would provide deeper insights into DE
diagnosis and follow-up.Non-contact confocal microscopy
A non-contact, tandem-scanning confocal microscope
demonstrating real-time images has been used by some
researchers to observe the tear film.39. Debris was discovered
in the central corneal region of tear film in dry and normal
eyes. They concluded that the minimal alteration of tear film
function and excellent focusing characteristics makes this a
valuable tool for detailed imaging of tear film.
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Confocal microscopy
Corneal in vivo confocal microscopy (IVCM) is a novel,
noninvasive, high-resolution tool that allows imaging the
cornea at the cellular level and provides images comparable
to histochemical methods. IVCM enables the study of corneal
epithelium, corneal stroma and keratocytes, endothelial cells,
corneal nerves, corneal immune and inflammatory cells,
conjunctiva and meibomian glands in different ocular and
systemic diseases that is not possible with direct slit-lamp
examination. It may not only be used for diagnostic
purposes, but may also serve as a valuable tool to monitor
the disease and measure therapeutic efficacy in patients with
DE. It is has been suggested that this technique could be
used for non-invasive impression cytology in DE evaluation.40
IVCM observations in DE patients demonstrated signifi-
cantly decreased cell densities in the superficial, intermedi-
ate, and basal epithelial layers,41 presumably due to
increased desquamation of the superficial cell layer42 and
activation of corneal keratocytes in the stroma.43 IVCM also
demonstrated a substantial decrease in number and density
of sub-basal and stromal nerve cells in DE related conditions.
Further, IVCM has demonstrated the abnormal morphology
of sub-basal nerves such as increase in bead-like formation,
sprouts, tortuosity, irregular branching patterns, and neuro-
mas, which may be explained by nerve degeneration and
regeneration, leading to active neural growth.44 More
recently, the non-invasive assessment of immune and inflam-
matory changes has become possible by laser IVCM that
allows visualization of the cell components that could not
be visualized earlier with previous white light IVCM machines.
This is of particular interest in DE patients as over the past
decade, the role of inflammation in DE disease has become
clearly apparent. This technique could be used for non-inva-
sive impression cytology.40 The increased density of epithe-
lial dendritic cells (Langerhans cells) observed by Lin et al.
may indicate the heightened immune status of the cornea
in DE.45 Dynamic in vivo assessment of the central corneal
inflammatory cell density may serve as an indicator of DE
severity and provide new insight for DE treatment. Recently,
IVCM has also been applied for the examination of meibomi-
an glands, providing a new tool to assess their morphologic
changes.46 Finally, IVCM evaluation of conjunctival epithe-
lium in DE demonstrated conjunctival epithelial cyst forma-
tion, decreased density of conjunctival epithelial cells,
goblet cells and increased inflammatory cell density.47,48Meibomian gland evaluation
Meibomian glands are the source of lipids in the lipid layer
of the tear film. Since MGD is the most common cause of
evaporative dry eye, the International Workshop on MGD
recommended performing gland expression routinely for all
asymptomatic patients.49 Meibomian glands can be assessed
visually using a slit lamp and an appropriate grading sys-
tem.50 Meiboscopy involves the trans-illumination of the eye-
lid using a white light, which has been described as ‘‘useful,
quick and patient-friendly’’.51 Meibography is a method of
quantification of meibomian gland drop-out that enables
masked evaluation and therefore increases objectivity inclinical trials.52 Meibometry involves the use of a plastic tape
to blot the central lower lid margin. The lipid blot changes
the optical density and can be measured in a photometer
to distinguish patients with MGD.53
Corneal and conjunctival staining
Corneal and conjunctival staining is an invasive procedure
which enables the assessment of ocular surface damage by
instilling a dye such as sodium fluorescein, rose bengal, or
lissamine green. Evaluation of ocular surface staining is highly
subjective, but the use of charts such as the Oxford, Van Bij-
sterveld, and CLEK grading scheme can facilitate consistent
recording of staining severity.54 The repeatability of staining
tests has been found to be poor,55 and they lack discrimina-
tory power in mild to moderate cases of dry eye.56
The SS International Registry modified the Oxford grading
scheme to enable concurrent grading of the cornea and
bulbar conjunctiva using a combination of one drop of
0.5% fluorescein for corneal staining and one drop of 1%
lissamine green for conjunctival staining. On a specially
designed form, grades between 0 and 3 are assigned for
staining the cornea, the nasal and the temporal conjunctiva.
This gives a maximum possible total of 9 points. Three addi-
tional points are then allocated for fluorescein only if there
are confluent staining (t1), staining in the pupillary area (t1),
or if one or more filaments are present (t1), giving a
maximum possible score of 12. This study concluded that
this would be a suitable test ‘‘for diagnosing the ocular
component of SS in future classification criteria’’.57
Conjunctival impression cytology or brush cytology
Impression cytology is a rapid, minimally invasive, and rel-
atively painless method of harvesting conjunctival epithelial,
goblet, and inflammatory cells from the bulbar mucosa.58
Studies have demonstrated that cytokines IL-1a, mature IL-1b,
and IL-1Ra are found in a significantly greater percentage of
conjunctival cytology specimens from eyes with SS, than in
those from normal eyes.59 Further, combined with flow
cytometry, dry eye group was found to have a significant dif-
ference in the CD4/CD8 ratio compared with normal eyes,
and almost double the number of CD14 positive cells (mono-
cytes/macrophages). HLA-DR expression in CK19 positive
conjunctival epithelial cells and matrix metalloproteinases lev-
els were also found to be elevated in DE patients.59,60 These
studies illustrate how immune cells isolated from the superfi-
cial layer of the conjunctiva may influence the pathogenesis of
DE. Flow cytometry analysis of epithelial and immune cells of
the conjunctiva may emerge as new biomarkers of DE.
Conjunctival brush cytology using a soft brush obtains
superficial cells (as in impression cytology) as well as basal
cells. The sample can then be assessed for the presence of
squamous metaplasia, inflammatory cells, and the expression
of surface markers on the ocular surface epithelium.61,62 This
is often combined with flow cytology, which gives a highly
sensitive and specific analysis of epithelial cell markers,
inflammatory cells, and goblet cells.62
Other tests
Fluorophotometry measures the uptake of fluorescein at
the center of the cornea and is considered ‘‘a sensitive
Dry eye disease 177measure of epithelial integrity’’.63 As such, patients with DE
demonstrate an increased corneal permeability and a slower
rate of fluorescein elimination compared to patients with nor-
mal eyes. A correlation between tear cytokine levels and the
severity of symptoms and ocular surface signs in all forms of
DE has been found.64 Tear protein analysis and tear lipid
analysis may provide more information on the etiology of
DE as different tear proteins are present in DE with or with-
out meibomian gland disease.64,65 While the mild cases of
DE exhibit normal tear production levels with no fluorescein
staining, an increase in inflammatory cells could still be
present. This indicates that inflammatory mediators in the
tears are perhaps a better indicator of DE disease than
the measure of tear production or staining. Recent advances
in tear lipid analysis technology and instrumentation have
seen huge progress in the field of lipidomics, which involves
the identification and quantification of lipid molecular species
and their interactions with other molecules, which can be
used to diagnose MGD.66Treatment
Only a handful of therapies are available for DE patients
and are used according to the disease severity.67 Artificial
tears provide palliative relief to eye irritation in patients with
aqueous tear deficiency, but do not prevent the underlying
inflammation or reverse conjunctival squamous metaplasia
in chronic DE. Combinations of artificial tears, oral omega-3
essential fatty acid supplements, mucin secretagogues,
short-term steroids, and daily cyclosporine A (CsA) are used
to combat underlying inflammation and restore normal tear
film in patients with mild-to-moderate disease. Use of more
aggressive treatment options, such as autologous serum,
oral tetracyclines, prosthetic lens, and systemic immune-
suppressants is restricted to patients with more severe forms
of DE. The most severe forms of chronic DE, often associated
with systemic diseases – SS and Stevens–Johnson syndrome,
may benefit from surgical intervention, including tarsorrha-
phy and amniotic membrane transplant. The Delphi panel
suggested that the severity of disease (categorized accord-
ing to patient’s signs and symptoms, not tests) should be
the primary determinant for the therapeutic strategy chosen.
Additionally, a stepwise guide to approach the best combi-
nation of medications to avoid symptoms of DE was also
recommended.3Anti-inflammatory treatments
Cyclosporine A
Inflammation is a key pathogenic factor in DE. Cyclospor-
ine A (CsA) exerts immunosuppressive and anti-inflammatory
activity through several pathways. Since the 1980s, several
reports highlighted that topical CsA can be used to treat a
variety of ocular inflammatory conditions including DE,
high-risk corneal transplants, autoimmune uveitis, and vernal
keratoconjunctivitis. Recent studies have shown that topical
administration of CsA not only controls ocular surface inflam-
mation, but is also effective in increasing tear secretion and
tear film stability (possibly by promoting the local release of
parasympathetic nervous system and through an increase in
goblet cell density). Consequently, CsA may help in restoringepithelial damage, and reducing disease recurrences over
the long term.68
Topical CsA significantly alleviates the signs and symp-
toms of DE and is often prescribed for long-term use by
eye care practitioners. The cumulative findings of several clin-
ical trials using 0.05% CsA ophthalmic emulsion for long-term
have indicated improvement in both objective (like corneal
surface staining and Schirmer test with anesthesia) and, sub-
jective findings (like blurred vision and frequency of artificial
tear application).69 In addition, topical CsA treatment may
be associated with a significant improvement in many of
the cellular and molecular markers of disease severity.70
Although higher dosing frequencies may increase treatment
efficacy, some patients experience bothersome adverse
effects (e.g., burning or irritation) that impair medication
tolerability. The beneficial effects of CsA treatment in DE
are well established; however, many patients with DE do
not show a consistent therapeutic response to topical CsA.
Steroids
Topical steroids are also used to dampen inflammation on
the ocular surface in DE, often in combination with CsA. The
effect of corticosteroids on the inflammatory cascade, specif-
ically the blockade of cyclooxygenase, production of prosta-
noids from arachidonic acid and stimulation of the apoptosis
of lymphocytes, is well known and is likely the reason this
form of therapy has been efficacious in practice.71 Corticoste-
roids also exert local immuno-modulatory activity through
the inhibition of certain transcription factor activity. Clinical
trials have demonstrated the efficacy of topical corticosteroid
treatment at diminishing symptom severity and minimizing
ocular surface staining.72 Unfortunately, long term topical
or systemic corticosteroid use is associated with deleterious
adverse effects, such as ocular hypertension, cataracts, and
opportunistic infections. Repetitive short-term pulsatile
administration of topical corticosteroids is a promising
method of harnessing their beneficial effects, while minimiz-
ing the risk of adverse events.73
Hormonal therapy
Receptors for androgens, estrogens, progesterone and
prolactin have been identified in several ocular tissues,
including the lacrimal gland and meibomian glands.74–76
Experimental and human studies have demonstrated that
adequate androgen, prolactin and estrogen levels are essen-
tial for normal lacrimal gland function and structural organiza-
tion.77–79 Administration of topically applied androgen and
estrogen steroid hormones for 3–4 months has also been
found to show clinical improvement in the form of increased
tear production TBUT and lipid layer thickness with corre-
sponding symptomatic relief. 80,81 Systemic replacement with
combined esterified estrogen and methyl-testosterone for
4–24 months was found to reduce symptoms and promote
clinical improvement in postmenopausal women with DE.82
Antibiotics
In addition to the antibacterial effect, macrolide antibiot-
ics (azithromycin) and tetracycline derivatives (tetracycline,
doxycycline, and minocycline) have immunomodulatory
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inflammation and normalize lipid production by the meibomi-
an glands. These may be particularly useful in dry eye second-
ary to ocular rosacea and blepharitis.83 Experimental
investigations have demonstrated that the tetracycline
derivative, doxycycline, can inhibit c-Jun N-terminal kinase,
extracellular signal-related kinase and mitogen-activated
protein kinase signaling in epithelial cells of the ocular surface
exposed to hyperosmolar stress. Additionally, doxycycline is
also known to down-regulate the expression of CXCL8 and
proinflammatory cytokines IL-1b and TNF84 and inhibit the
activity of MMPs (e.g., MMP-9).85 Similarly, the tetracycline
derivative minocycline inhibits the expression of cell associ-
ated pro-inflammatory molecules.86 Despite extensive
evidence from experimental trials indicating the potential
benefits of administration of tetracycline derivatives in the
treatment of DE, clinical evidence of their efficacy remains
limited.87Supplementary treatments
Essential Fatty Acids (EFAs)
Omega-3 (alpha-linolenic acid) and omega-6 (linoleic acid)
are biologically necessary fatty acids that must be ingested
because they cannot be synthesized de novo by the human
body. EFAs are the precursors of eicosanoids (prostaglan-
dins, prostacyclins, thromboxanes, and leukotrienes) that
modulate immune responses; while omega-3 FAs are
generally classified as anti-inflammatory, omega-6 FAs are
considered proinflammatory.88 Investigations on the use of
EFAs in the treatment of DE have produced conflicting
results; however, most of the available evidence suggests
that systemic administration of anti-inflammatory omega-3
FAs, can lessen DE severity.89,90 Topical EFAs have also been
evaluated in murine DE models and showed potential thera-
peutic effect in the form of decreased ocular surface staining,
cytokine expression, and immune cell infiltration.91 Similarly,
topical administration of resolvin E1, an omega-3 FA
derivative increased tear production, helped maintain ocular
surface integrity, decreased cyclooxygenase 2 expression,
and decreased immune cell infiltration in experimental dry
eye.92 Available data suggest that using EFAs to treat dry
eye disease is a promising frontier in ocular surface
therapeutics and worthwhile subject for future research in
DE; however, more evidence is needed to identify the most
efficacious forms and doses of EFAs.Nerve growth factor (NGF)
NGF has been observed to increase ocular surface sensi-
tivity, inhibit inflammatory reactions and regulate tear film
production.93 Thus, NGF seems to a play a pivotal role in
the pathophysiology of DE and may be a promising thera-
peutic option.94 Data from several studies seem to be sup-
porting this hypothesis. For instance, tear concentration of
NGF has been observed to be increased as a compensatory
mechanism in DE,94 particularly under hyperosmolar stress,95
suggesting that NGF may be involved in reducing the apop-
tosis of corneal epithelial cells triggered by hyperosmolarity.
Additionally, NGF has been shown to regulate conjunctival
epithelial differentiation into MUC5AC-secreting gobletcells.96. Therefore, exogenous NGF administration may be
beneficial in recovering ocular surface damage due to chronic
hyperosmolarity; for example, topical NGF administration
has been observed to increase tear production and
conjunctival goblet cell density in a dog experimental model
of dry eye.97
Autologous serum
Autologous and umbilical cord serum contains substances
that support the proliferation, differentiation, and maturation
of the normal ocular surface epithelium98 and therefore, finds
application in the treatment of severe DE.99 In 1984, Fox and
colleagues reported the beneficial effects of autologous
serum in SS.100 Documenting similar findings, Tsubota and
Bradley attributed the improvements to the presence of
EGF, vitamin A, lysozyme, fibronectin and TGF-beta.101,102
Autologous serum eye drops have been found to be better
than conventional therapy utilizing artificial tears in less
severe cases of DE as well. For instance, a prospective
randomized, controlled, crossover study comparing 50%
autologous serum eye drops with conventional therapy utiliz-
ing artificial tear solutions confirmed that ocular surface vital
staining score and cytological improvements were due to
serum drops, as the effects were reversed when treatment
was reverted to conventional therapy.103 Similarly, another
double-blind randomized clinical trial reported that a
short-term treatment with 20% autologous serum eye
drops achieved better symptomatic improvement than con-
ventional artificial tears in DE patients.104
Acupuncture
The use of acupuncture as a treatment for eye disease is
based on the claims that acupuncture modulates autonomic
nervous system and immune system,105,106 which in turn
might regulate lacrimal gland function. It therefore seems
pertinent to evaluate the effectiveness of acupuncture as a
treatment for DE. To date, more than 70 papers have exam-
ined the effect of acupuncture in treating DE. While some
authors have suggested that acupuncture can influence lacri-
mal gland secretions,107 others have postulated that it can
alleviate pain intensity (or increase pain threshold).108Surgical treatment
Punctal occlusion
Punctal occlusion reduces drainage, preserves natural
tears and prolongs the effect of lubricants. It is indicated in
patients refractory to medical treatment, having a Schirmer
test (with anesthesia) result of less than 5 mm at 5 min, and
showing the evidence of ocular surface dye staining.109
Several techniques of punctal occlusion have been studied.
For instance, temporary occlusion that dissolves in 1 or
2 weeks can be achieved by inserting collagen plugs into
the canaliculi. Long-lasting collagen plugs that take
2–6 months to dissolve are also available. Silicon plugs are
commonly used as reversible prolonged occlusion. Punctal
occlusion using atelocollagen causes fewer complications
when compared to insoluble plugs.110 Permanent punctal
occlusion may be achieved surgically using cauterization.
Dry eye disease 179Combined use of punctal plugs and cyclosporine 0.05%
demonstrated better improvement in Schirmer scores and
rose bengal staining, and reduced overall artificial tear use
compared to either treatment alone. 111
Salivary gland procedures
Surgical procedures involving salivary glands for the
management of DE have been explored since 1951, when
Filatov and Chevalijev described the parotid duct transfer
to the conjunctival fornix.112 Murube described the transfer
of the submandibular salivary gland to the temporal region
and implant of the Wharton duct into the upper fornix.113
Studies have also reported the use of a graft of labial mucosa
and minor salivary glands to treat severe dry eye.114 Soares
and Franca have routinely performed this surgery in their
clinic in Brazil between 2000 and 2004115 on patients with
severe dry eye caused by Stevens–Johnson syndrome,
chemical burns, pemphigoid, SS, and surgical removal of
the lacrimal gland. The patients reported a subjective relief
in DE symptoms immediately after surgery.
Subcutaneous abdominal artificial tear pump-reservoir
The artificial tear pump-reservoir was suggested by Murube
for the treatment of severe dry eye.116 It was implanted into a
subcutaneous pocket of the anterolateral abdominal wall and
the silicon tube catheter is passed via chest, neck and face to
the upper conjunctival fornix.
Conclusion
In conclusion, the understanding of the pathogenesis and
specific cellular responses involved in different forms of DE
could result in the development of other treatment strategies
for a better management and long lasting results. The evi-
dence implicating inflammation in the pathogenesis of DE
has opened up new avenues for the treatment of this com-
plex disorder. Development of additional treatment options
in the form of compounds targeting specific components
such as the epithelial barrier, corneal nerves, conjunctival
goblet cells, or immune cells and cytokines involved in the
ocular inflammatory reaction would provide hope for the
millions of individuals who daily experience this deleterious
condition.
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